Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lupin Evades U.S. Patent Battle With Warner Chilcott For Oral Contraceptives

This article was originally published in PharmAsia News

Executive Summary

WASHINGTON - Indian generic drug maker Lupin may have cleared a big hurdle in its pursuit to launch generic versions of Warner Chilcott's oral contraceptive drugs Loestrin 24 Fe and Femcon in the United States as the Irish company - specializing in dermatology and women's health products - decided to back out from a patent lawsuit it filed at the U.S. District Court of Maryland

You may also be interested in...



Lupin Wants To Go Generic With Nexium; AstraZeneca Feels The Heartburn

MUMBAI - Challenging product patents and later reaching a settlement with innovator companies have emerged as a strong business model for Indian generic drug maker Lupin. After settling at least five patent cases over the last two years, Lupin has now taken on AstraZeneca claiming non-infringement of Nexium (esomeprazole) patents in the United States

Lupin Wants To Go Generic With Nexium; AstraZeneca Feels The Heartburn

MUMBAI - Challenging product patents and later reaching a settlement with innovator companies have emerged as a strong business model for Indian generic drug maker Lupin. After settling at least five patent cases over the last two years, Lupin has now taken on AstraZeneca claiming non-infringement of Nexium (esomeprazole) patents in the United States

India's Lupin Strengthens Its Brand Presence With Oscient Pharma's Antara

MUMBAI - For Lupin - the fast emerging Indian generic drug maker - the switch from pure generic drugs in the U.S. to a patented and branded play is happening faster than many analysts expected. Lupin made an audacious $38.61 million bid for bankruptcy-threatened Oscient Pharma's top cardiovascular drug Antara (fenofibrate), and finally clinched the deal while outpacing at least three other generic rivals

UsernamePublicRestriction

Register

LL1129367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel